300
Participants
Start Date
December 28, 2016
Primary Completion Date
December 1, 2018
Study Completion Date
May 31, 2020
Tislelizumab
Administered intravenously
Cancer Hospital Chinese Academy of Medical Sciences, Beijing
Beijing Cancer Hospital, Beijing
Harbin Medical University Cancer Hospital, Harbin
Fudan University Shanghai Cancer Center, Shanghai
Affiliated Zhongshan Hospital of Fudan University, Shanghai
Jiangsu Province Hospital, Nanjing
Zhejiang University College of Medicine Second Affiliated Hospital, Hangzhou
Sir Run Run Shaw Hospital, Zhejiang University School of Medicine, Hangzhou
The First Affiliated Hospital of Nanchang University Branch Donghu, Nanchang
Sun Yat Sen Memorial Hospital, Sun Yat Sen University (North), Guangzhou
Guangdong Provincial Peoples Hospital, Guangzhou
The Fifth Affiliated Hospital Sun Yat Sen University, Zhuhai
Lead Sponsor
BeiGene
INDUSTRY